Gérardin, Marie, Rousselet, Morgane, Couec, Marie-Laure, Masseau, Agathe, Chantalat, Christelle, Driss, Françoise, Guitton, Corinne, Debbache, Karima, Foïs, Elena, Galacteros, Frédéric, Habibi, Anoosha, Léon, Anne, Mattioni, Sarah, Santin, Aline, Alexis-Fardini, Scylia, Augusty, Edima, Billaud, Marie, Divialle-Doumdo, Lydia, Etienne-Julan, Maryse, and Lemonne, Nathalie
Background: In many countries, nitrous oxide is used in a gas mixture (EMONO) for short-term analgesia. Cases of addiction, with significant misuse, have been reported in hospitalized patients. Patients suffering from sickle cell disease (SCD) could represent a high-risk population for substance use disorder (SUD) due to their significant pain crisis and repeated use of EMONO. The objective of the PHEDRE study was to assess the prevalence of SUD for EMONO in French SCD patients. Results: A total of 993 patients were included. Among 339 EMONO consumers, only 38 (11%) had a SUD, with very few criteria, corresponding mainly to a mild SUD due to a use higher than expected (in quantity or duration) and relational tensions with the care teams. Almost all patients (99.7%) were looking for an analgesic effect, but 68% of patients were also looking for other effects. The independent risks factors associated with at least one SUD criterion were: the feeling of effects different from the expected therapeutic effects of EMONO, at least one hospitalization for vaso occlusive crisis in the past 12 months and the presence of a SUD for at least one other analgesic drug. Conclusions: The use of EMONO was not problematic for the majority of patients. Manifestations of SUD that led to tensions with healthcare teams should alert and lead to an evaluation, to distinguish a true addiction from a pseudoaddiction which may be linked to an insufficient analgesic treatment related to an underestimation of pain in SCD patients. Trial registration: Clinical Trials, NCT02580565. Registered 16 October 2015, https://clinicaltrials.gov/ [ABSTRACT FROM AUTHOR]